Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 9, 2004, Pages 1294-1299

  Bertolotto, A ^a   Sala, A ^a   Malucchi, S ^a   Marnetto, F ^a   Caldano, M ^a   Di Sapio, A ^a   Capobianco, M ^a   Gilli, F ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; MESSENGER RNA; NEUTRALIZING ANTIBODY;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOGENIC EFFECT; DRUG ACTIVITY; EVALUATION; FEMALE; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SERUM;

ANTIBODY FORMATION; BIOLOGICAL RESPONSE MODIFIERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 4344660973     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.037259     Document Type: Article

References (36)

1. IFN beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multi-center randomized, double-blind, placebo controlled trial. Neurology 1993;43:655-61.
2. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
4. European Study Group of Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-97.
5. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82.
6. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS, Neurology 2001;56:1628-36.
7. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular Interferon Beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
8. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-94.
9. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical significance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-91.
10. Deisenhammer F, Reindel M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-43.
11. Vallittu AM, Halminen M, Peltoniemi J, et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta 1a-treated MS patients. Neurology 2002;58:1786-90.
12. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 2003;60:634-9.
13. Pachner AR. Anti-IFNβ antibodies in IFNβ-treated MS patients. Neurology 2003;61(suppl 5):S1-S5.
14. ser in healthy volunteers and its effects on serum neopterin. Pharmacol Res 1993;10:567-72.
15. Witt PL, Storer BE, Bryan GT, et al. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β. J Immunother 1993;13:191-200.
16. Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron® and Avonex™. J Interferon Cytokine Res 1998;18:967-75.
17. von Wussow P, Jakschies D, Hochkeppel HK, et al. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990;20:2015-19.
18. Kracke A, von Wussow P, Al-Masri AN, et al. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000;54:193-9.
19. Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001;256:141-52.
20. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003;61(suppl 5):S24-S26.
21. Gilli F, Sala A, Bancone C, et al. Evaluation of IFNα bioavailability by MxA mRNA in HCV patients. J Immunol Methods 2002;262:183-86.
22. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
23. Bertolotto A, Malucchi S, Milano E, et al. Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000;48:95-100.
24. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res 1998;18:345-50.
25. Kawade Y. Quantitation of neutralization of interferon by antibodies. Methods Enzymol 1986;119:558-73.
26. Grossberg SE, Kawade Y, Kohase M, et al. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit, J Interferon Cytokine Res 2001;21:743-55.
27. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in multiple sclerosis patients: a follow-up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-53.
28. Rothuizen LE, Buclin T, Spertini F, et al. Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999;99:131-41.
29. Dupont SA, Goelz S, Goyal J, et al. Mechanisms for regulation of cellular responsiveness to human IFN-beta 1a. J Interferon Cytokine Res 2002;22:491-501.
30. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000;48:706-12.
31. Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines and multiple sclerosis. Neurology 1998;50:1294-300.
32. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
33. Arnason BGW, Dayal A, Qu ZX, et al. Mechanisms of action of interferon-β in multiple sclerosis. Semin Immunopathol 1996;18:125-48.
34. Kastrukoff LF, Morgan NG, Zecchini D, et al. Natural killer cells in relapsing remitting MS: effects of treatment with interferonβ-1b. Neurology 1999;52:351-9.
35. Paul WE, Sender RA. Lymphocyte responses and cytokines. Cell 1994;76:241-51.
36. Gilli F, Bertolotto A, Sala A, et al. Neutralising antibodies against IFN-β in MS: antagonisation of IFN-β mediated suppression of MMPs. Brain 2004;127(Pt 2):259-68.